Previous close | 4.6200 |
Open | 4.7000 |
Bid | 4.3800 x 400 |
Ask | 4.4100 x 200 |
Day's range | 4.3450 - 4.7050 |
52-week range | 1.1800 - 9.3900 |
Volume | |
Avg. volume | 1,790,850 |
Market cap | 501.522M |
Beta (5Y monthly) | N/A |
PE ratio (TTM) | N/A |
EPS (TTM) | N/A |
Earnings date | N/A |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | N/A |
Exploring the Financial Landscape and Future Prospects Amidst Regulatory Advances
The U.S. Food and Drug Administration has extended its review of Applied Therapeutics' experimental drug to treat galactosemia, a rare genetic metabolic disease, the company said on Thursday. There are currently no approved treatments for the disease in the United States, which has about 3,000 Galactosemia patients. The FDA delayed its decision on the drug, govorestat, saying it requires additional time to review supplemental analyses submitted by the company.
Applied Therapeutics (APLT) surges 124% in a month due to encouraging updates from two separate developmental programs for govorestat to treat different rare neurological indications.